Pharmanovia Enters In-Licensing Agreement With Axsome Therapeutics to Market and Further Develop Sunosi (solriamfetol), a First-In-Class Treatment for Excessive Daytime Sleepiness (EDS) in People With Narcolepsy and Obstructive Sleep Apnoea
The Agreement Covers All Existing Territories in Europe and Any Future Launches Across the Region Pharmanovia Will Also Lead All Activities to Support the Launch of Sunosi (solriamfetol) Across Middle
Dennis Riedl Herriot Tabuteau James Burt Alison Dyson Axsome Therapeutics Inc Agreement Covers All Existing Territories
Source: finanznachrichten.de